Recent

% | $
Quotes you view appear here for quick access.

SAVİENT PHARM AŞ Message Board

hdmitv 33 posts  |  Last Activity: Feb 3, 2016 7:25 AM Member since: Sep 6, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I set 0.73 buy 75K shares when market open.

    Sentiment: Strong Buy

  • I set buy 100K GBSN

    Sentiment: Strong Buy

  • %1000 BEBE will close in great mall this weekend not even 5 peoles buy BEBE cloths. For sure BEBE will be body next

    Let me tell you guys why, bebe too much fake sold in Vietnam and china. only $1 US for 1 bebe tshirt

    Sentiment: Strong Sell

  • Guys bee ready to see under 0.10 on tuesday........ Someone set big sell off, something wrong with GBSN

    Sentiment: Strong Sell

  • Sell all GALE all in THLD.THLD on fire Feb will see triple. GALE will below 0.50 than RS

    Sentiment: Strong Sell

  • THLD another 2 on 6-30-2016 please see link below

    biopharmcatalyst.com/fda-calendar/

    Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results

    SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/02/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter 2015. Revenue for the third quarter ended September 30, 2015 was $3.7 million. The operating loss for the third quarter ended September 30, 2015 was $6.8 million. The net loss for the third quarter ended September 30, 2015 was $6.4 million, which included the operating loss of $6.8 million and non-cash income of $0.3 million related to the changes in fair value of the Company's outstanding warrants and was classified as other income (expense). As of September 30, 2015, Threshold had $56.4 million in cash, cash equivalents and marketable securities, with no debt outstanding.

    "This is an exciting time for Threshold as we anticipate announcing top-line results from the two pivotal Phase 3 clinical trials of evofosfamide in patients with advanced soft tissue sarcoma (TH-CR-406) and in patients with advanced pancreatic cancer (MAESTRO) around the end of this year," said Barry Selick, Ph.D., Chief Executive Officer at Threshold. "In the third quarter, we also made significant progress with tarloxotinib, our exclusively-licensed hypoxia-activated EGFR tyrosine kinase inhibitor, with the initiation of two proof-of-concept Phase 2 clinical trials. We expect to have preliminary data from those trials in the first half of 2016."

    Third Quarter 2015 Financial and Operational Results

    Revenue of $3.7 million was recognized for both the third quarter of 2015 and 2014. Revenue is related to the amortization of the aggregate of $110 million in upfront and milestone payments earned in 2013 and 2012 from Threshold's collaboration with Merck KGaA, Darmstadt, Germany, for evofosfamide (previously known as TH-302). The revenue from the upfront and mile Less

    Sentiment: Strong Buy

    Sentiment: Strong Buy

  • THLD another 2 on 6-30-2016 please see link below

    biopharmcatalyst.com/fda-calendar/

    Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results

    SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/02/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter 2015. Revenue for the third quarter ended September 30, 2015 was $3.7 million. The operating loss for the third quarter ended September 30, 2015 was $6.8 million. The net loss for the third quarter ended September 30, 2015 was $6.4 million, which included the operating loss of $6.8 million and non-cash income of $0.3 million related to the changes in fair value of the Company's outstanding warrants and was classified as other income (expense). As of September 30, 2015, Threshold had $56.4 million in cash, cash equivalents and marketable securities, with no debt outstanding.

    "This is an exciting time for Threshold as we anticipate announcing top-line results from the two pivotal Phase 3 clinical trials of evofosfamide in patients with advanced soft tissue sarcoma (TH-CR-406) and in patients with advanced pancreatic cancer (MAESTRO) around the end of this year," said Barry Selick, Ph.D., Chief Executive Officer at Threshold. "In the third quarter, we also made significant progress with tarloxotinib, our exclusively-licensed hypoxia-activated EGFR tyrosine kinase inhibitor, with the initiation of two proof-of-concept Phase 2 clinical trials. We expect to have preliminary data from those trials in the first half of 2016."

    Third Quarter 2015 Financial and Operational Results

    Revenue of $3.7 million was recognized for both the third quarter of 2015 and 2014. Revenue is related to the amortization of the aggregate of $110 million in upfront and milestone payments earned in 2013 and 2012 from Threshold's collaboration with Merck KGaA, Darmstadt, Germany, for evofosfamide (previously known as TH-302). The revenue from the upfront and mile

    Sentiment: Strong Buy

  • Another 2 on 6-30-2016 please see link below

    biopharmcatalyst.com/fda-calendar/

    Threshold Pharmaceuticals Reports Third Quarter 2015 Financial and Operational Results

    SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/02/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter 2015. Revenue for the third quarter ended September 30, 2015 was $3.7 million. The operating loss for the third quarter ended September 30, 2015 was $6.8 million. The net loss for the third quarter ended September 30, 2015 was $6.4 million, which included the operating loss of $6.8 million and non-cash income of $0.3 million related to the changes in fair value of the Company's outstanding warrants and was classified as other income (expense). As of September 30, 2015, Threshold had $56.4 million in cash, cash equivalents and marketable securities, with no debt outstanding.

    "This is an exciting time for Threshold as we anticipate announcing top-line results from the two pivotal Phase 3 clinical trials of evofosfamide in patients with advanced soft tissue sarcoma (TH-CR-406) and in patients with advanced pancreatic cancer (MAESTRO) around the end of this year," said Barry Selick, Ph.D., Chief Executive Officer at Threshold. "In the third quarter, we also made significant progress with tarloxotinib, our exclusively-licensed hypoxia-activated EGFR tyrosine kinase inhibitor, with the initiation of two proof-of-concept Phase 2 clinical trials. We expect to have preliminary data from those trials in the first half of 2016."

    Third Quarter 2015 Financial and Operational Results

    Revenue of $3.7 million was recognized for both the third quarter of 2015 and 2014. Revenue is related to the amortization of the aggregate of $110 million in upfront and milestone payments earned in 2013 and 2012 from Threshold's collaboration with Merck KGaA, Darmstadt, Germany, for evofosfamide (previously known as TH-302). The revenue from the upfront and milestone payments earned under the agreement is being amortized over the relevant performance period, rather than being immediately recognized when the upfront and milestone payments are earned or received.

    The net loss for the third quarter of 2015 was $6.4 million compared to a net loss of $7.7 million for the third quarter of 2014. Included in the net loss for the third quarter of 2015 was an operating loss of $6.8 million and non-cash income of $0.3 million compared to an operating loss of $7.6 million and non-cash expense of $0.3 million included in the net loss for the third quarter of 2014. The non-cash income or expense is related to the change in fair value of the Company's outstanding warrants and was classified as other income (expense).

    Research and development expenses were $8.1 million for the third quarter of 2015 compared to $8.9 million for the third quarter of 2014. The decrease in research and development expenses was due primarily to a $1.1 million net decrease in clinical development expenses, net of reimbursement from Merck KGaA, Darmstadt, Germany related to their 70% share of total development expenses for evofosfamide. The decrease in clinical development expenses was due to a decrease in clinical development expenses for evofosfamide, partially offset by an increase in clinical development expenses for tarloxotinib.

    General and administrative expenses were $2.4 million for both the third quarter of 2015 and 2014.

    Non-cash stock-based compensation expense included in total operating expenses was $1.5 million for the third quarter of 2015 versus $1.2 million for the third quarter of 2014. The increase in stock-based compensation expense was due to the amortization of a greater number of options with higher fair values.

    As of September 30, 2015 and June 30, 2015, Threshold had $56.4 million and $67.0 million in cash, cash equivalents and marketable securities, respectively. The net decrease of $10.6 million in cash, cash equivalents and marketable securities during the third quarter of 2015 was primarily due to the Company's operating cash requirements for the third quarter of 2015.

    Corporate Highlights

    Announced the appointment of Mark Hopkins, J.D., Ph.D., as Vice President of Intellectual Property and Assistant General Counsel. In this newly created position, Dr. Hopkins oversees worldwide intellectual property strategy and activities related to further advancement of Threshold's intellectual property portfolio for its investigational anti-cancer therapeutics, evofosfamide and tarloxotinib, and hypoxia-activated prodrug technology. Dr. Hopkins is also responsible for oversight of corporate legal matters at Threshold.

    Threshold- and Merck KGaA, Darmstadt, Germany-Sponsored Trials of Evofosfamide: Clinical Development Highlights and Outlook

    Announce top-line data from the two pivotal Phase 3 clinical trials. The companies are focused on efficient execution of the two Phase 3 clinical trials of evofosfamide: one in patients with advanced soft tissue sarcoma (TH-CR-406) and the other in patients with advanced pancreatic cancer ("MAESTRO"). The current expectations are that top-line data will be announced around the end of 2015 for both trials and that the companies will prepare for potential submission of marketing applications, assuming the data from the trials are supportive.

    Continue enrollment in the Phase 2 non-squamous non-small cell lung cancer clinical trial. Threshold is conducting a 440-patient, randomized, double-blind, placebo-controlled trial of evofosfamide in combination with pemetrexed in patients with second-line advanced non-squamous non-small cell lung cancer. This international Phase 2 clinical trial is designed to support registration and will compare the combination of evofosfamide plus pemetrexed versus pemetrexed plus placebo as second-line therapy in this patient population. Overall survival is the primary endpoint. Enrollment in the trial is ongoing.

    Commence enrollment in final cohort of the Phase 1/2 multiple myeloma clinical trial. Threshold plans to initiate dosing with the combination of evofosfamide, dexamethasone, and Pomalyst® (pomalidomide, an immunomodulatory drug) in up to 38 patients with relapsed/refractory multiple myeloma in the final cohort of its ongoing Phase 1/2 trial. A total of 62 patients have been enrolled in the trial in which the safety and efficacy of evofosfamide plus dexamethasone with or without Velcade® (bortezomib, a proteasome inhibitor) was assessed.

    Threshold-Sponsored Trials of Tarloxotinib Bromide*: Clinical Development Highlights and Outlook

    Initiated patient dosing in Phase 2 non-small cell lung cancer clinical trial. In August, Threshold announced that the Company, in collaboration with the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), initiated the first Phase 2 clinical trial of tarloxotinib for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer who have been previously treated with an EGFR tyrosine kinase inhibitor and are progressing on treatment, but have not acquired the T790M resistance mutation. The trial is expected to enroll up to 37 patients; preliminary data are expected to be available in the first half of 2016.

    Initiated patient dosing in Phase 2 squamous cell carcinomas clinical trial. In August, Threshold announced initiation of dosing in a Phase 2 clinical trial of tarloxotinib for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. The trial is expected to enroll up to 69 patients; preliminary data are expected to be available in the first half of 2016.

    Sentiment: Strong Buy

  • THLD will see approval By FDA in Feb!!!! 3 to 4 soon

    Sentiment: Strong Buy

  • BEBEQ.PK within 3 months, during holiday went to BEBE store in great mall milpitas like ghost town, no one walk in, BEBE cloths in Asia too much fake. China / Taiwan / Thailand / Vietnam all fake bebe sell for $1 each

    Sentiment: Strong Sell

  • hdmitv hdmitv Dec 30, 2015 10:11 AM Flag

    Google it!

    Sentiment: Strong Buy

  • hdmitv hdmitv Dec 30, 2015 10:10 AM Flag

    Yes, I hear that news too buy out in talk, look like we get $2.8 or 3 PPs. Happy new year. News out any time.

    Sentiment: Strong Buy

  • If THLD not doing anything within 30 days is JUNK

    Sentiment: Strong Sell

  • Reply to

    Mother F you Harold E. Selick Ph.D., 61

    by hdmitv Dec 24, 2015 10:19 AM
    hdmitv hdmitv Dec 26, 2015 9:05 AM Flag

    who the F LAURA? Over All this is the garbage americans cheap company Threshold Pharmaceuticals Inc., over all are junk americans doctor worker in there

    Sentiment: Strong Sell

  • Hope this big news hope will see back to $3 or 4

    Sentiment: Strong Buy

  • Mother F you all below, have a bad holdays to all of you. All garbage

    Dr. Harold E. Selick Ph.D., 61
    Exec. Chairman and Chief Exec. Officer 847.00K 0.00
    Mr. Joel A. Fernandes , 45
    VP of Fin. and Controller 351.00K 0.00
    Dr. Nipun Davar Ph.D., MBA, 47
    Sr. VP of Pharmaceutical Devel. & Manufacturing 374.00K 0.00
    Dr. Tillman E. Pearce M.D., 58
    Chief Medical Officer 524.00K 0.00
    Mr. Robert L. Simon , 70
    Sr. VP of Regulatory Affairs & Quality Assurance 433.00K 0.00

    Sentiment: Strong Sell

  • Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC (TH-4000)

    This study is currently recruiting participants. (see Contacts and Locations)

    Verified October 2015 by Threshold Pharmaceuticals

    Sponsor:

    Threshold Pharmaceuticals

    Information provided by (Responsible Party):

    Threshold Pharmaceuticals

    ClinicalTrials.gov Identifier:

    NCT02454842

    First received: May 4, 2015

    Last updated: November 24, 2015

    Last verified: October 2015

    History of Changes

    Full Text View
    Tabular View
    No Study Results Posted
    Disclaimer
    How to Read a Study Record


    No Study Results Posted on ClinicalTrials.gov for this Study

    About Study Results Reporting on ClinicalTrials.gov

    Study Status:
    This study is currently recruiting participants.

    Estimated Study Completion Date:
    December 2016

    Estimated Primary Completion Date:
    December 2016 (Final data collection date for primary outcome measure)

    2017

    Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS

    This study is currently recruiting participants. (see Contacts and Locations)

    Verified October 2015 by Threshold Pharmaceuticals

    Sponsor:

    Threshold Pharmaceuticals

    Information provided by (Responsible Party):

    Threshold Pharmaceuticals

    ClinicalTrials.gov Identifier:

    NCT02449681

    First received: May 12, 2015

    Last updated: November 10, 2015

    Last verified: October 2015

    History of Changes

    Full Text View
    Tabular View
    No Study Results Posted
    Disclaimer
    How to Read a Study Record


    No Study Results Posted on ClinicalTrials.gov for this Study

    About Study Results Reporting on ClinicalTrials.gov

    Study Status:
    This study is currently recruiting participants.

    Estimated Study Completion Date:
    No date given

    Estimated Primary Completion Date:
    January 2017 (Final data collection date for primary outcome measure)

    2017 Japan

    A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

    This study is currently recruiting participants. (see Contacts and Locations)

    Verified October 2015 by Merck KGaA

    Sponsor:

    Merck KGaA

    Collaborator:

    Threshold Pharmaceuticals

    Information provided by (Responsible Party):

    Merck KGaA

    ClinicalTrials.gov Identifier:

    NCT02255110

    First received: September 30, 2014

    Last updated: October 19, 2015

    Last verified: October 2015

    History of Changes

    Full Text View
    Tabular View
    No Study Results Posted
    Disclaimer
    How to Read a Study Record


    No Study Results Posted on ClinicalTrials.gov for this Study

    About Study Results Reporting on ClinicalTrials.gov

    Study Status:
    This study is currently recruiting participants.

    Estimated Study Completion Date:
    July 2017

    Estimated Primary Completion Date:
    January 2017 (Final data collection date for primary outcome measure)

    Sentiment: Strong Buy

  • this going to approve

    THERAPEUTICS: Tarloxotinib (TH-4000)

    TH-CR-601

    Non-Small Cell Lung Cancer

    This phase 2 study is designed to evaluate the safety and activity of TH-4000, a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced non-small cell lung cancer (NSCLC). Read more about this study on ClinicalTrials.gov


    TH-CR-602

    Head & Neck Squamous Cell Carcinoma

    This phase 2 study is designed to evaluate the safety and activity of TH-4000, a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. Read more about this study on ClinicalTrials.gov

    Sentiment: Strong Buy

  • hdmitv hdmitv Dec 18, 2015 6:16 PM Flag

    that good sign for buy out...... mask it.

    Sentiment: Strong Buy

  • Look like someone offer buy out AH, hope see you guy $5 or 7 on MONDAY

    Sentiment: Strong Buy

SVNTQ
0.00(0.00%)